Director/PDMR Shareholding - Replacement

RNS Number : 3423A

Dechra Pharmaceuticals PLC

06 June 2016

 

The announcement below replaces an announcement released on 6 June 2016 under RNS number 3271A. In that announcement the highest price paid was £11.4070 and should be £11.434 as below.

6 June 2016

Dechra^® Pharmaceuticals PLC

("Dechra" or "the Company")

Director / PDMR shareholding 

Dechra Pharmaceuticals PLC has been notified that on 3 June 2016 Tony Rice, Non-Executive Director, purchased 20,000 ordinary shares in the Company at an average price of £11.407 each.  The highest price paid was £11.434 and the lowest £11.38

Following this acquisition, Tony Rice's beneficial interest in the Company is 20,000 shares (0.02% of the current issued share capital).

For further information, please contact:

Suzana Cross, General Counsel and Company Secretary            

Telephone number: 01606 814730

About Dechra

Dechra is an international specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information please visit: www.dechra.com

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

 

END

 

 

DSHBSGDLIGGBGLL